Table 4.

Characteristics of secukinumab use of patients with AS (N = 78)

Characteristic	Patients with AS (N = 78)
Duration of treatment with secukinumaba
Mean (SD), months	4.7 (4.6)
Median (IQR), months	3.5 (1.0–6.0)
Dose
Initial loading dose, n (%)
150 mg every weekb	31 (39.7)
300 mg every weekc	42 (53.8)
Otherd	1 (1.3)
No loading dose	4 (5.1)
Received maintenance dose, n (%)
Initial maintenance dosee
150 mg every 4 weeks	41 (56.2)
300 mg every 4 weeks	32 (43.8)
Current use of secukinumab, n (%)
Patient still receiving secukinumab	74 (94.9)
Patient discontinued secukinumab	3 (3.8)
Reason for secukinumab discontinuation, n (%)f
Lack/loss of efficacy/effectiveness	2 (66.7)
Patient request	1 (33.3)
Otherg	1 (33.3)
Unknown status of secukinumab use	1 (1.3)

AS ankylosing spondylitis, IQR interquartile range

^aDuration of treatment with secukinumab was calculated among all patients; the calculated duration underestimates the true duration because most patients were still receiving secukinumab at the time of the survey

^bAmong the 31 patients who initiated secukinumab at 150 mg every week, 24 received an initial maintenance dose of 150 mg every 4 weeks, five received 300 mg every 4 weeks, and two did not remain on the therapy long enough to receive maintenance treatment

^cAmong the 42 patients who initiated secukinumab at 300 mg every week, 14 received an initial maintenance dose of 150 mg every 4 weeks, 26 received 300 mg every 4 weeks, and two did not remain on the therapy long enough to receive maintenance treatment

^dOther initial loading dose included “methotrexate”

^eThe proportions of initial maintenance doses were calculated among patients who received a maintenance dose

^fThe proportions of reasons for discontinuation were calculated among patients who discontinued secukinumab. Multiple reasons could be selected for each patient

^gOther reason included “patient deceased”